Search PubMed⌕ Search

PubMed · 39662679

Regulating IL-2 Immune Signaling Function Via A Core Allosteric Structural Network.

Abstract

Human interleukin-2 (IL-2) is a crucial cytokine for T cell regulation, with therapeutic potential in cancer and autoimmune diseases. However, IL-2's pleiotropic effects across different immune cell types often lead to toxicity and limited efficacy. Previous efforts to enhance IL-2's therapeutic profile have focused on modifying its receptor binding sites. Yet, the underlying dynamics and intramolecular networks contributing to IL-2 receptor recognition remain unexplored. This study presents a detailed characterization of IL-2 dynamics compared to two engineered IL-2 mutants, "superkines" S15 and S1, which exhibit biased signaling towards effector T cells. Using NMR spectroscopy and molecular dynamics simulations, we demonstrate significant variations in core dynamic pathways and conformational exchange rates across these three IL-2 variants. We identify distinct allosteric networks and minor state conformations in the superkines, despite their structural similarity to wild-type IL-2. Furthermore, we rationally design a mutation (L56A) in the S1 superkine's core network, which partially reverts its dynamics, receptor binding affinity, and T cell signaling behavior towards that of wild-type IL-2. Our results reveal that IL-2 superkine core dynamics play a critical role in their enhanced receptor binding and function, suggesting that modulating IL-2 dynamics and core allostery represents an untapped approach for designing immunotherapies with improved immune cell selectivity profiles.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Claire H Woodward, Shahlo O Solieva, Daniel Hwang, Viviane S De Paula, Charina S Fabilane, Michael C Young, Tony Trent, Ella C Teeley, Ananya Majumdar, Jamie B Spangler, Gregory R Bowman, Nikolaos G Sgourakis. 2024-12-09. Regulating IL-2 Immune Signaling Function Via A Core Allosteric Structural Network.. https://doi.org/10.1016/j.jmb.2024.168892

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction.

Nuclear magnetic resonance (NMR) methods were employed to study the interaction of the cytokine Interleukin-2 (IL-2) with the alpha-subunit of its receptor (IL-2Ralpha), and to help understand the behavior of small molecule inhibitors of this interaction. Heteronuclear (1)H-(15)N HSQC experiments were used to identify the interaction surface of (15)N-enriched Interleukin-2 ((15)N-IL-2) in complex with human IL-2Ralpha. In these experiments, chemical shift and line width changes in the heteronuclear single-quantum coherence (HSQC) spectra upon binding of (15)N-IL-2 enabled classification of NH atoms as either near to, or far from, the IL-2Ralpha interaction surface. These data were complemented by hydrogen/deuterium (H/D) exchange measurements, which illustrated enhanced protection of slowly-exchanging IL-2 NH protons near the site of interaction with IL-2Ralpha. The interaction surface defined by NMR compared well with the IL-2Ralpha binding site identified previously using mutagenesis of human and murine IL-2. Two low molecular weight inhibitors of the IL-2/IL-2Ralpha interaction were studied: one (a cyclic peptide derivative) was found to mimic a part of the cytokine and bind to IL-2Ralpha; the other (an acylphenylalanine derivative) was found to bind to IL-2. For the interaction between IL-2 and the acylphenylalanine, chemical shift perturbations of (15)N and (15)NH backbone resonances were tracked as a function of ligand concentration. The perturbation pattern observed for this complex revealed that the acylphenylalanine is a competitive inhibitor-it binds to the same site on IL-2 that interacts with IL-2Ralpha.

Interleukin-2↗

Blocking of T cell activation at the G1A/G1B interface of the cell cycle and prevention of expression of interleukin 2 receptors by alloactivated suppressor T lymphocytes.

Suppressor T (Ts) leukocytes affect various immune reactions including the activation of T cells by alloantigens. It is, however, not known where Ts interfere with the sequence of events supporting T cell activation and proliferation. In the present studies, alloantigen selective Ts were activated by in vitro priming with heat-inactivated allogeneic leukocytes in the mixed leukocyte reaction (MLR). Such Ts, or a soluble factor thereof, were shown to interfere with the progression of MLR responder cells from the G1A to the G1B phase of the cell cycle. In the presence of Ts, most MLR responder cells did not express interleukin 2 receptors, although a small minority of cells constantly escaped Ts inhibition. Moreover, Ts modified MLR contained only minor interleukin 2 (IL-2) bioactivity suggesting also an effect of Ts cells on IL-2 synthesis. The addition of exogenous IL-2 to Ts modified MLR increased 3H-thymidine incorporation although Ts retained the capacity to regulate the proliferative response in a dose-dependent fashion. Phenotypic analysis of allostimulated T cells proliferating in the presence of preformed Ts and exogenous IL-2 revealed a conspicuous failure of T helper cells to proliferate in response to alloantigen despite the presence of very high IL-2 concentrations.

Interleukin-2↗